Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-025-07313-z
Abstract: To evaluate tumour and normal organ dosimetry of PSMA-targeted RLT 177Lu-rhPSMA-10.1. PSMA-positive mCRPC patients experiencing disease progression following standard-of-care treatment were enrolled and underwent ≤ 3 cycles of 5.55 or 7.40 GBq 177Lu-rhPSMA-10.1 at 6-week intervals. Multi-bed… read more here.
Keywords: rhpsma; 177lu rhpsma; psma targeted; anatomy ... See more keywords
Utility of Novel Radiohybrid PSMA Ligands in PET Imaging of Biochemical Recurrence of Prostate Cancer—A Systematic Review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000005641
Abstract: Purpose: Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a novel class of radiopharmaceuticals developed for potential theranostic application in prostate cancer (PCa). We aimed to consolidate existing evidence on utility of 18F-rhPSMA-7/7.3 for PET imaging… read more here.
Keywords: pet imaging; rhpsma; prostate; utility ... See more keywords